PATENT APPLICATION No.: 10/564,825 ATTORNEY DOCKET No.: 58767,000011

## AMENDMENTS TO THE CLAIMS

This listing of the claims below will replace all prior versions and listing of claims in this application.

Claims 1-10. (Canceled)

- 11. (New) A method of treating terminal-phase pulmonary distress comprising administering a therapeutically effective quantity of botulinum toxin to a patient suffering from terminal-phase pulmonary distress.
- 12. (New) The method of claim 11, wherein said patient suffers from death rattle.
- 13. (New) The method of claim 11, wherein said botulinum toxin is a botulinum toxin of Type A, B, C, D, E, F and G.
- (New) The method of claim 13, wherein said botulinum toxin is a botulinum toxin of Type A. B or F.
- (New) The method of claim 13, wherein said botulinum toxin is a botulinum toxin of Type A or B.
- (New) The method of claim 13, wherein said botulinum toxin is a botulinum toxin of Type A<sub>1</sub>, A<sub>2</sub>, A<sub>3</sub>, C<sub>1</sub> or C<sub>2</sub>.
- 17. (New) The method of claim 13, wherein said botulinum toxin is Type A botulinum toxin.
- 18. (New) The method of claim 11, wherein said therapeutically effective quantity is a dose of 20 to 2000 LD on units of type A botulinum toxin per patient.
- (New) The method of claim 11, wherein said therapeutically effective quantity is a dose of 50 to 1000 LD<sub>50</sub> units of type A botulinum toxin per patient.
- 20. (New) The method of claim 11, wherein said therapeutically effective quantity comprises a dose of 100 to 500 LD<sub>50</sub> units of type A botulinum toxin per patient.
- (New) The method of claim 11, wherein said therapeutically effective quantity comprises a dose of approximately 250 LD<sub>50</sub> units of type A botulinum toxin per patient.

PATENT APPLICATION No.: 10/564,825 ATTORNEY DOCKET No.: 58767.000011

- (New) The method of claim 11, wherein said botulinum toxin is in the form of a lyophilized powder.
- (New) The method of claim 11, wherein said botulinum toxin is in the form of an injectable solution.
- 24. (New) The method of claim 11, wherein said botulinum toxin is injected into the parotid gland or the tensor veli palatini muscle of said patient.
- 25. (New) The method of claim 11, wherein said patient suffers from a brain tumor, lung cancer or a terminal-stage neurodegenerative disease.
- 26. (New) A method of preventing terminal-phase pulmonary distress comprising administering a therapeutically effective quantity of botulinum toxin to patient suffering from terminal-phase pulmonary distress.
- (New) The method of claim 26, wherein said botulinum toxin is a botulinum toxin of Type A, B, C, D, E, F and G.
- 28. (New) The method of claim 26, wherein said botulinum toxin is Type A botulinum toxin.
- (New) The method of claim 26, wherein said therapeutically effective quantity comprises a dose of approximately 150 LD<sub>50</sub> units of type A botulinum toxin per patient.
- (New) The method of claim 25, wherein said patient suffers from a brain tumor, lung cancer or a terminal-stage neurodegenerative disease.